US FDA approves atezolizumab plus chemotherapy for metastatic NSCLC

Written by Rachel Jenkins, Oncology Central

It has been announced that the US FDA has approved the combination of Tecentriq® (atezolizumab) plus chemotherapy (nab-paclitaxel and carboplatin) for the initial treatment of metastatic non-squamous non-small cell lung cancer (NSCLC) patients with no EGFR or ALK genomic tumor aberrations. The approval follows positive data from the Phase III IMpower130 clinical trial. This multicenter, open-label, randomized study enrolled 724 individuals who were randomized (2:1) to receive atezolizumab plus carboplatin and nab-paclitaxel (Arm A), or carboplatin and nab-paclitaxel (Arm B, control arm). Find out more about IMpower130 here. The trial demonstrated that atezolizumab plus chemotherapy increased median overall survival compared...

To view this content, please register now for access

It's completely free